Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN3 | Q9UGI6 | 3/20 | 0.72 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19686804 | 0.92 | KCNN3 (0.73) | KCNN3KCNN2ALOX15POLBTP53 | |
| SCHEMBL20444097 | 0.88 | KCNN2 (0.56) | KCNN3KCNN2ALOX15POLBTP53 | |
| SCHEMBL19686938 | 0.87 | KCNN3 (0.67) | KCNN3KCNN2ALOX15POLBTP53 | |
| SCHEMBL4207857 | 0.85 | KCNN3 (0.97) | KCNN3KCNN2ALOX15POLBTP53 | |
| SCHEMBL19686620 | 0.84 | KCNN3 (0.57) | KCNN3KCNN2ALOX15POLBTP53 | |
| SCHEMBL25191245 | 0.84 | KCNN3 (0.77) | KCNN3KCNN2ALOX15POLBTP53 | |
| SCHEMBL29355074 | 0.84 | KCNN3 (1.00) | KCNN3KCNN2ALOX15POLBTP53 | |
| SCHEMBL3233745 | 0.84 | KCNN3 (1.00) | KCNN3KCNN2ALOX15POLBTP53 | |
| SCHEMBL19686594 | 0.82 | KCNN2 (0.57) | KCNN3KCNN2ALOX15POLBTP53 | |
| SCHEMBL19686958 | 0.82 | KCNN3 (0.57) | KCNN3KCNN2ALOX15POLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215746-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215746-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK10, KCNJ1 | KCNN3 13/4885KCNN2 7/4885ALOX15 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.